Sotorasib for people with brain tumors needing surgery
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests a drug called sotorasib in people with brain tumors who are already scheduled for surgery or a biopsy. It may help find out if the drug can reach and treat the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a brain tumor that needs surgery or a biopsy.
- You are capable of doing most daily tasks on your own (Karnofsky score of 60 or higher).
- Your doctor expects you to live more than 12 weeks.
- Your blood counts, kidney, and liver function must be within safe limits before starting treatment.
- You must wait long enough after previous treatments for side effects to get better.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two drugs (asciminib alone or with sildenafil) for people with brain tumors that have come back or are growing. The goal is to see if these drugs can help shrink or control the tumor.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This Phase 2 study tests sotorasib (also called AMG510) in people with Stage III lung cancer that cannot be removed by surgery and that has a specific KRAS mutation (p.G12C). You may be able to join if you cannot safely receive chemo-radiotherapy at the same time, and the study checks whether sotorasib can help shrink or control the cancer.
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
Hear when a new Brain Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.